drugset / Trial / NCT02213055

Pediatric Head Lice Study Product Comparison

NCT02213055

Phase 2 Completed 97 enrolled Hackensack Meridian Health
Non-randomizedParallel-groupOpen-labelTreatment

Summary

* To evaluate the efficacy of LiceMD for the treatment of head lice in a pediatric population. * To evaluate the safety of LiceMD in a pediatric population.

Timeline

Start
2009-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dimethicone Unknown 100 %
Comparator Lindane Small molecule 1 %
Comparator Malathion Small molecule 0.5 %
Comparator Permethrin Small molecule 1 %
Comparator Permethrin Small molecule 5 %